Publicaciones en colaboración con investigadores/as de Instituto Ramón y Cajal de Investigación Sanitaria (30)

2024

  1. Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy

    Journal of Experimental and Clinical Cancer Research, Vol. 43, Núm. 1

  2. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells

    Gut, Vol. 73, Núm. 9, pp. 1489-1508

  3. The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer

    Familial Cancer, Vol. 23, Núm. 3, pp. 383-392

  4. The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no known pathogenic germline variants

    Familial Cancer, Vol. 23, Núm. 3, pp. 233-246

2023

  1. Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

    Journal of Visualized Experiments, Vol. 2023, Núm. 195

2022

  1. Cyclooxygenase 2 Effector Genes as Potential Inflammation-Related Biomarkers for Colorectal Cancer Circulating Tumor Cells Detection by Liquid Biopsy

    Frontiers in Pharmacology, Vol. 12

  2. Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case-Control Studies

    Environmental health perspectives, Vol. 130, Núm. 5, pp. 57006

  3. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

    Gut, Vol. 72, Núm. 2, pp. 345-359

  4. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis

    eBioMedicine, Vol. 75

2021

  1. Biomarkers associated with regorafenib first-line treatment benefits in metastatic colorectal cancer patients: Reframe molecular study

    Cancers, Vol. 13, Núm. 7

  2. Correction: Earl et al. Somatic mutation profiling in the liquid biopsy and clinical analysis of hereditary and familial pancreatic cancer cases reveals kras negativity and a longer overall survival. Cancers 2021, 13, 1612

    Cancers

  3. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study

    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), Vol. 30, Núm. 6, pp. 423-430

  4. Somatic mutation profiling in the liquid biopsy and clinical analysis of hereditary and familial pancreatic cancer cases reveals kras negativity and a longer overall survival

    Cancers, Vol. 13, Núm. 7

2020

  1. A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective

    ESMO Open, Vol. 5, Núm. 5

  2. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants

    EBioMedicine, Vol. 53

  3. Braf mutated colorectal cancer: New treatment approaches

    Cancers, Vol. 12, Núm. 6, pp. 1-15

  4. Bratislava Statement: Consensus recommendations for improving pancreatic cancer care

    ESMO Open, Vol. 5, Núm. 6

  5. Current and future role of tyrosine kinases inhibition in thyroid cancer: From biology to therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 14, pp. 1-29

  6. Epigenetic landscape in pancreatic ductal adenocarcinoma: On the way to overcoming drug resistance?

    International Journal of Molecular Sciences, Vol. 21, Núm. 11, pp. 11-17

  7. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity

    Nature Communications, Vol. 11, Núm. 1